The results showed that higher FGF21 levels were not associated with the risk of all-cause death among patients with CAD (HR: 1.86, 95% CI: 0.89–3.87, P > 0.05, I2 = 90%, random-effect model; Figure 3A). Here, FGF21 is linked to coronary artery disorder.